Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Therapeutic drug monitoring: an aid to optimising response to antiretroviral drugs?

Aarnoutse RE, Schapiro JM, Boucher CA, Hekster YA, Burger DM.

Drugs. 2003;63(8):741-53. Review.

PMID:
12662123
2.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
3.

Improving HIV infection management using antiretroviral plasma drug levels monitoring: a clinician's point of view.

Clevenbergh P, Mouly S, Sellier P, Badsi E, Cervoni J, Vincent V, Trout H, Bergmann JF.

Curr HIV Res. 2004 Oct;2(4):309-21. Review.

PMID:
15544452
4.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
5.

Effects of age on antiretroviral plasma drug concentration in HIV-infected subjects undergoing routine therapeutic drug monitoring.

Winston A, Jose S, Gibbons S, Back D, Stohr W, Post F, Fisher M, Gazzard B, Nelson M, Gilson R, Orkin C, Johnson M, Palfreeman A, Chadwick D, Leen C, Schwenk A, Anderson J, Gompels M, Dunn D, Khoo S, Sabin C; UK Collaborative HIV Cohort Study.

J Antimicrob Chemother. 2013 Jun;68(6):1354-9. doi: 10.1093/jac/dkt029. Epub 2013 Feb 23.

PMID:
23435690
6.

Therapeutic drug monitoring of antiretrovirals for people with HIV.

Kredo T, Van der Walt JS, Siegfried N, Cohen K.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD007268. doi: 10.1002/14651858.CD007268.pub2. Review.

PMID:
19588422
7.

The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.

Schoenenberger JA, Aragones AM, Cano SM, Puig T, Castello A, Gomez-Arbones X, Porcel JM.

Ther Drug Monit. 2013 Feb;35(1):71-7. doi: 10.1097/FTD.0b013e3182791f8c.

PMID:
23188184
8.

Practical guidelines to interpret plasma concentrations of antiretroviral drugs.

Kappelhoff BS, Crommentuyn KM, de Maat MM, Mulder JW, Huitema AD, Beijnen JH.

Clin Pharmacokinet. 2004;43(13):845-53. Review.

PMID:
15509183
9.

Clinical benefit of interventions driven by therapeutic drug monitoring.

Rendón A, Núñez M, Jiménez-Nácher I, González de Requena D, González-Lahoz J, Soriano V.

HIV Med. 2005 Sep;6(5):360-5.

10.

GENOPHAR: a randomized study of plasma drug measurements in association with genotypic resistance testing and expert advice to optimize therapy in patients failing antiretroviral therapy.

Bossi P, Peytavin G, Ait-Mohand H, Delaugerre C, Ktorza N, Paris L, Bonmarchand M, Cacace R, David DJ, Simon A, Lamotte C, Marcelin AG, Calvez V, Bricaire F, Costagliola D, Katlama C.

HIV Med. 2004 Sep;5(5):352-9.

11.

Therapeutic drug monitoring of nelfinavir and indinavir in treatment-naive HIV-1-infected individuals.

Burger D, Hugen P, Reiss P, Gyssens I, Schneider M, Kroon F, Schreij G, Brinkman K, Richter C, Prins J, Aarnoutse R, Lange J; ATHENA Cohort Study Group.

AIDS. 2003 May 23;17(8):1157-65.

PMID:
12819517
12.

Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: can they be applied to the current situation?

Ribera E, López-Cortés LF, Soriano V, Casado JL, Mallolas J.

Enferm Infecc Microbiol Clin. 2005 Jul;23 Suppl 2:41-67. Review. English, Spanish.

PMID:
16373004
13.

Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.

Cruciani M, Mengoli C, Serpelloni G, Parisi SG, Malena M, Bosco O.

Cochrane Database Syst Rev. 2013 Jun 5;(6):CD008270. doi: 10.1002/14651858.CD008270.pub2. Review.

PMID:
23740608
14.

Protease inhibitor plasma concentrations in HIV antiretroviral therapy.

Justesen US.

Dan Med Bull. 2008 Nov;55(4):165-85. Review.

PMID:
19232158
15.

Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography.

Notari S, Bocedi A, Ippolito G, Narciso P, Pucillo LP, Tossini G, Donnorso RP, Gasparrini F, Ascenzi P.

J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Feb 2;831(1-2):258-66. Epub 2006 Jan 6.

PMID:
16406832
16.

Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.

Mbuagbaw L, Mursleen S, Irlam JH, Spaulding AB, Rutherford GW, Siegfried N.

Cochrane Database Syst Rev. 2016 Dec 10;12:CD004246. doi: 10.1002/14651858.CD004246.pub4. Review.

17.

Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.

[No authors listed]

Prescrire Int. 2004 Aug;13(72):144-50.

PMID:
15532140
18.

Adherence to HIV therapeutic drug monitoring guidelines in The Netherlands.

van Luin M, Wit FW, Smit C, Rigter IM, Franssen EJ, Richter C, Kroon F, de Wolf F, Burger DM.

Ther Drug Monit. 2011 Feb;33(1):32-9. doi: 10.1097/FTD.0b013e318205b81d.

PMID:
21192311
19.

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Bazzoli C, Jullien V, Le Tiec C, Rey E, Mentré F, Taburet AM.

Clin Pharmacokinet. 2010;49(1):17-45. doi: 10.2165/11318110-000000000-00000. Review.

PMID:
20000887
20.

Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.

Fabbiani M, Di Giambenedetto S, Bracciale L, Bacarelli A, Ragazzoni E, Cauda R, Navarra P, De Luca A.

J Antimicrob Chemother. 2009 Jul;64(1):109-17. doi: 10.1093/jac/dkp132. Epub 2009 Apr 27.

PMID:
19398461

Supplemental Content

Support Center